瑞舒伐他汀对老年冠状动脉支架植入术后患者空腹血糖的影响  

Effect of Rosuvastatin on fasting plasma glucose after coronary stent implantation in elderly patients

作　　者：吴芳芳 赵小燕[2] 张金岭[3] 李峥嵘[4] 王玉强[1] 田涛[5] Wu Fangfang;Zhao Xiaoyan;Zhang Jinling;Li Zhengrong;Wang Yuqiang;Tian Tao(Department of Cardiology,Linyi People's Hospital,Shandong University,Linyi 276003,China;Department of Pharmacy,Chinese Medicine Hospital in Linyi City,Linyi 276002,China;Cerntral Laboratory,Linyi People's Hospital,Shandong University,Linyi 276003,China;Department of Pharmacy,Linyi People's Hospital,Shandong University,Linyi 276003,China;Department of Geriatrics,Linyi People's Hospital,Shandong University,Linyi 276003,China)

机构地区：[1]山东大学附属临沂市人民医院心内科,临沂276003 [2]临沂市中医医院药学部,临沂276002 [3]山东大学附属临沂市人民医院中心实验室,临沂276003 [4]山东大学附属临沂市人民医院药学部,临沂276003 [5]山东大学附属临沂市人民医院老年病科,临沂276003

出　　处：《中华老年医学杂志》2019年第11期1216-1219,共4页Chinese Journal of Geriatrics

基　　金：山东省自然科学基金(ZR2018BH032);山东省医药卫生科技发展计划项目(2015WS0367);临沂市2018年度医疗卫生科技发展计划项目(201818008)。

摘　　要：目的探讨瑞舒伐他汀对老年非糖尿病患者冠状动脉支架植入术后空腹血糖的影响。方法选择2015年11月至2018年4月在临沂市人民医院心血管内科行冠状动脉支架植入术并出院后在我院门诊随诊的老年非糖尿病患者216例,回顾性收集患者的人口统计学资料、随访时间、入院时和最后1次门诊随诊的实验室检查结果。结果216例患者平均随访10.5个月,191例基线空腹血糖(FPG)正常患者随访结束时较基线升高(t=-3.783,P=0.000);糖尿病前期组患者新发糖尿病(NOD)发生率(24.0%)高于血糖正常组患者(2.6%)(χ^2=16.72,P=0.000)。结论瑞舒伐他汀会升高老年非糖尿病患者冠状动脉支架植入术后空腹血糖水平,糖尿病前期可能会增加瑞舒伐他汀相关的NOD风险。Objective To investigate the effect of Rosuvastatin on fasting plasma glucose after coronary stent implantation in elderly patients with non-diabetes mellitus.Methods A total of 216 non-diabetic elderly patients undergoing coronary stent implantation in our hospital from November 2015 to April 2018 were enrolled,with a follow-up in the cardiovascular department after discharge from the Hospital.The demographic data,follow-up time,and laboratory results at hospital admission and the last outpatient visit were collected retrospectively.Results At the end of follow-up,Fasting plasma glucose(FPG)was increased in 191 patients with normal baseline FPG level as compared with the baseline level(t=-3.783,P=0.000).The incidence of new-onset diabetes was higher in the pre-diabetes group than in the normal blood glucose group(24.0%vs.2.6%,χ^2=16.72,P=0.000).Conclusions Rosuvastatin increases fasting blood glucose levels in elderly non-diabetic patients after coronary stent implantation.Pre-diabetes may increase the risk for rosuvastatin-associated new-onset diabetes.

关 键 词：冠状动脉疾病 血糖 

分 类 号：R[医药卫生]